Ovarian cancer drug combo trial halted early – what we know

NCT ID NCT05756907

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug combination (SON-1010 plus atezolizumab) in people with advanced solid tumors, especially platinum-resistant ovarian cancer. The goal was to see if the combination was safe and could slow tumor growth. The trial was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ashford Cancer Centre Research

    Kurralta Park, South Australia, 5037, Australia

  • Blacktown Mt Druitt Hospital

    Blacktown, New South Wales, 2148, Australia

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Sarcoma Oncology Center

    Santa Monica, California, 90403, United States

  • The Border Cancer Hospital

    Albury, New South Wales, 2640, Australia

  • University of Southern California

    Los Angeles, California, 90033, United States